{"entity":{"id":"cll-ipi","kind":"term","name":"CLL-IPI (chronic lymphocytic leukaemia prognostic index)","aka":["CLL-IPI","CLL International Prognostic Index","CLL-IPI score","beta-2 microglobulin in CLL","B2M in CLL","very high risk CLL","high-risk CLL"],"tldr":"CLL-IPI scores five things at diagnosis (TP53 loss or mutation, unmutated IGHV, raised beta-2 microglobulin, advanced stage and age over 65) to predict time to first treatment and survival; TP53 and IGHV are the two that still change which drug is chosen, because they decide whether chemo-immunotherapy is ever an option.","summary":"What is measured: prognosis in chronic lymphocytic leukaemia. How: CLL-IPI (2016) gives 4 points for del(17p) or TP53 mutation, 2 for unmutated IGHV, 2 for serum beta-2 microglobulin above 3.5 mg/L, 1 for Binet B or C (Rai I to IV) and 1 for age over 65, giving low (0 to 1), intermediate (2 to 3), high (4 to 6) and very high (7 to 10) risk with five-year survival of about 93, 79, 63 and 23 percent in the derivation data. Inputs: FISH for del(17p), TP53 sequencing, IGHV sequencing (under 98 percent identity to germline means mutated), serum beta-2 microglobulin and clinical staging. What a result changes: the score does not itself start treatment (the iwCLL criteria do); early-stage high-risk patients have been offered trials (CLL12 tested ibrutinib in early stage and delayed progression without improving survival); del(17p) or TP53 mutation rules out chemo-immunotherapy such as FCR for good, favouring continuous BTK inhibitors or venetoclax with obinutuzumab; unmutated IGHV predicts shorter remissions after fixed-duration therapy and is retested rarely because it does not change. Where it matters: CLL, treatment-naive.","asOf":"2026-09-17","links":[],"tags":[],"related":["del17p-tp53","ighv-status","staging-systems","fish","ibrutinib","acalabrutinib","zanubrutinib","venetoclax","obinutuzumab"],"cancers":["cll","cll-treatment-naive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Biomarkers"},"route":"/terms/cll-ipi/","neighbours":{"term":[{"id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","route":"/terms/del17p-tp53/"},{"id":"staging-systems","kind":"term","name":"Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)","route":"/terms/staging-systems/"},{"id":"fish","kind":"term","name":"FISH / ISH (in situ hybridisation)","route":"/terms/fish/"},{"id":"ighv-status","kind":"term","name":"IGHV mutational status","route":"/terms/ighv-status/"},{"id":"sf3b1-mutation","kind":"term","name":"SF3B1 mutation","route":"/terms/sf3b1-mutation/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"}]}}